DBV Technologies Secures €166.7 Million Financing to Support VIASKIN® Peanut Patch Launch
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Source: Globenewswire
- Successful Financing: DBV Technologies raised €166.7 million through the full exercise of 34,090,004 ABSA warrants and 71,005,656 BS warrants, ensuring sufficient operational funding for the next 12 months to support the upcoming commercial launch of the VIASKIN® Peanut patch.
- Dilution Impact: Following this financing, the company's shareholder equity per share decreased from €0.53 to €0.46, with ownership interest dropping from 1% to 0.78%, highlighting the dilution effect on existing shareholders while providing necessary funding for future product launches.
- Market Entry Plans: Proceeds will be utilized for preparing and submitting a Biologics License Application (BLA) and planning the launch of the VIASKIN® Peanut patch in the U.S., which, if approved, will offer new treatment options for children aged 4 to 7, addressing urgent market needs for food allergy treatments.
- Future Outlook: DBV Technologies anticipates that if all outstanding warrants are exercised, total financing could reach €284.5 million, further enhancing the company's financial stability and competitive position in the biopharmaceutical sector for long-term growth.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on DBVT
Wall Street analysts forecast DBVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DBVT is 46.40 USD with a low forecast of 40.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 23.770
Low
40.00
Averages
46.40
High
51.00
Current: 23.770
Low
40.00
Averages
46.40
High
51.00
About DBVT
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DBV Technologies Secures €166.7 Million Financing to Support VIASKIN® Peanut Patch Launch
- Successful Financing: DBV Technologies raised €166.7 million through the full exercise of 34,090,004 ABSA warrants and 71,005,656 BS warrants, ensuring sufficient operational funding for the next 12 months to support the upcoming commercial launch of the VIASKIN® Peanut patch.
- Dilution Impact: Following this financing, the company's shareholder equity per share decreased from €0.53 to €0.46, with ownership interest dropping from 1% to 0.78%, highlighting the dilution effect on existing shareholders while providing necessary funding for future product launches.
- Market Entry Plans: Proceeds will be utilized for preparing and submitting a Biologics License Application (BLA) and planning the launch of the VIASKIN® Peanut patch in the U.S., which, if approved, will offer new treatment options for children aged 4 to 7, addressing urgent market needs for food allergy treatments.
- Future Outlook: DBV Technologies anticipates that if all outstanding warrants are exercised, total financing could reach €284.5 million, further enhancing the company's financial stability and competitive position in the biopharmaceutical sector for long-term growth.
Continue Reading
DBV Technologies Secures €166.7 Million Financing to Support VIASKIN® Peanut Patch Launch
- Successful Financing: DBV Technologies has secured €166.7 million through the full exercise of ABSA and BS warrants, ensuring sufficient operational funding for the next 12 months to support the commercial readiness of the VIASKIN® Peanut patch.
- Equity Dilution Impact: The financing resulted in the issuance of 59,657,507 new shares, which is expected to dilute existing shareholders' ownership from 1% to 0.78%, impacting equity but providing necessary funding for future growth.
- Market Entry Plans: The proceeds will be utilized for a potential Biologics License Application (BLA) and the launch of the VIASKIN® Peanut patch in the U.S., which, if approved, will offer new allergy treatment options for children aged 4 to 7, addressing significant market needs.
- Future Outlook: If all outstanding pre-funded warrants are exercised, total financing could reach approximately €284.5 million, further enhancing the company's competitive position in the food allergy treatment sector.
Continue Reading